Physician profile
Daniel E O'Connell
NPI 1558605618
$6,403.33
in general payments reported to CMS, 2019-2025
28 companies · $2,594 in 2025
The $2,594 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,436 · 2024: $2,374 · 2025: $2,594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,403.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.21 | 2023-2025 | |
| Biogen, INC. | $637.22 | 2023-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $634.13 | 2023-2025 | |
| Eisai INC. | $596.39 | 2023-2025 | |
| Lilly USA, LLC | $499.37 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Lundbeck LLC | $464.68 | 2023-2025 | Vyepti |
| Ucb, INC. | $436.52 | 2024-2025 | Briviact, Nayzilam |
| Pfizer INC. | $339.16 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $337.74 | 2023-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $303.10 | 2023-2025 | Mavenclad, Mavenclad |
| Celgene Corporation | $213.42 | 2023-2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $174.93 | 2025 | |
| Neurelis, INC. | $125.42 | 2023 | Valtoco |
| Davol INC. | $107.33 | 2025 | Arista |
| Teva Pharmaceuticals USA, INC. | $106.37 | 2023-2024 | Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $65.25 | 2025 | Symbravo |
| Tanabe Pharma America, INC. | $51.04 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $46.48 | 2025 | Crexont |
| Amylyx Pharmaceuticals, INC. | $35.43 | 2023-2024 | Relyvrio |
| Averitas Pharma INC. | $29.68 | 2023 | Qutenza |
| Merz Pharmaceuticals, LLC | $23.90 | 2025 | Ampyra, Inbrija, Xeomin |
| Catalyst Pharmaceuticals, INC. | $22.73 | 2024 | |
| Tg Therapeutics, INC. | $22.45 | 2024 | |
| Boston Scientific Corporation | $20.27 | 2024 | Watchman Flx |
| Genentech USA, INC. | $19.28 | 2025 | Ocrevus Zunovo |
| Cala Health, INC. | $18.46 | 2023 | Cala Trio |
| Impel Pharmaceuticals INC. | $18.34 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $18.03 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel O'Connell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.